Maureen serves as the Secretariat and Legal Counsel of the International Pharmaceutical Aerosol Consortium (IPAC) and has been in the role since 2000. IPAC’s mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC has developed principles to help guide policy discussions that reflect the lessons learned in our work on the Montreal Protocol on Substances that Deplete the Ozone Layer. IPAC is comprised of AstraZeneca, Bespak, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GSK, Kindeva, Organon and Teva. IPAC members produce MDIs in the UK, Europe, United States and other countries and supply MDIs to patients worldwide.
She is based in Washington, DC and is also a partner at the law firm, Faegre, Drinker, Biddle & Reath, LLC.